Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Labcorp Holdings Inc. LH

Healthcare  —  Diagnostics & Research
309.64 0.69 0.22% as of 25 Sep
Market cap
$21.9B
P/E
25.4×
S&P 500 Member Dividend Champion (5y) Revenue Champion (3y)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Labcorp (LH) Business Profile

Updated before January 2025

Company Overview

Laboratory Corporation of America Holdings, commonly known as Labcorp, is a leading global life sciences company that provides comprehensive clinical laboratory and end-to-end drug development services. Founded in 1978 and headquartered in Burlington, North Carolina, Labcorp has grown to become one of the largest diagnostic testing companies in the world. The company was formed through the merger of Roche Biomedical Laboratories and National Health Laboratories, two prominent diagnostic companies at the time.

Labcorp is led by Adam H. Schechter, who serves as the Chairman, President, and Chief Executive Officer. Under his leadership, the company has focused on innovation, operational excellence, and expanding its global footprint. Labcorp operates in over 100 countries and employs more than 75,000 people worldwide, making it a key player in the healthcare and life sciences industries.

Core Business Segments

Labcorp operates through two primary business segments: Diagnostics and Drug Development. These segments encompass a wide range of products and services that cater to healthcare providers, pharmaceutical companies, and patients.

1. Diagnostics

Labcorp’s Diagnostics segment provides clinical laboratory testing services that help healthcare providers diagnose, monitor, and treat diseases. Key offerings include:

  • Routine Testing: Blood tests, urinalysis, and other routine diagnostic tests.
  • Specialty Testing: Advanced genetic testing, oncology diagnostics, and infectious disease testing.
  • Women’s Health: Prenatal screening, fertility testing, and other services tailored to women’s health.
  • COVID-19 Testing: Labcorp played a significant role in providing COVID-19 PCR and antibody testing during the pandemic.
  • Home Testing Services: Through its Pixel by Labcorp platform, the company offers at-home testing kits for various conditions, including cholesterol, diabetes, and sexually transmitted infections (STIs).

2. Drug Development (Covance)

Labcorp’s Drug Development segment, formerly known as Covance, provides contract research and development services to pharmaceutical and biotechnology companies. Key services include:

  • Clinical Trials: Phase I-IV clinical trial management and monitoring.
  • Preclinical Testing: Toxicology, pharmacology, and safety testing for drug candidates.
  • Regulatory Consulting: Assistance with regulatory submissions and compliance.
  • Biomarker Development: Identification and validation of biomarkers for drug development.
  • Companion Diagnostics: Development of diagnostic tools that complement specific therapies.

Business Model

Labcorp’s business model is built on integrating its diagnostic and drug development capabilities to provide a comprehensive suite of services. The company generates revenue through:

  • Diagnostic Testing Services: Fees charged to healthcare providers, hospitals, and patients for laboratory testing.
  • Contract Research Services: Payments from pharmaceutical and biotechnology companies for drug development and clinical trial services.
  • Partnerships and Collaborations: Strategic alliances with healthcare systems, academic institutions, and technology companies to expand its service offerings.
  • Direct-to-Consumer Testing: Revenue from at-home testing kits and online health services.

Labcorp’s integrated approach allows it to leverage data and insights from its diagnostics and drug development segments, creating synergies that enhance its value proposition to clients.

Strategic Direction

Labcorp is focused on several strategic priorities to drive future growth:

  • Expansion of Diagnostic Services: The company aims to broaden its test menu and enhance accessibility through digital platforms and home testing solutions.
  • Growth in Drug Development: Labcorp plans to invest in advanced technologies, such as artificial intelligence and machine learning, to streamline clinical trials and improve drug development outcomes.
  • Sustainability Goals: Labcorp is committed to reducing its environmental footprint by adopting sustainable practices in its operations and supply chain.
  • Global Expansion: The company is actively expanding its presence in emerging markets to tap into growing demand for healthcare services.
  • Innovation: Labcorp continues to invest in research and development to introduce new diagnostic tests and improve existing ones.

Competitive Landscape

Labcorp operates in a highly competitive environment, facing competition from both large multinational corporations and smaller regional players. Key competitors include:

  • Quest Diagnostics: A major competitor in the diagnostic testing market.
  • Eurofins Scientific: A global leader in laboratory testing services.
  • Charles River Laboratories: A competitor in the preclinical and clinical research space.
  • ICON plc and PPD: Competitors in the contract research organization (CRO) market.
  • Emerging Startups: Companies offering innovative at-home testing solutions and digital health platforms.

Labcorp differentiates itself through its integrated service model, extensive test menu, and global reach.

Risk Factors

Labcorp faces several risks that could impact its business operations and financial performance:

  • Market Dependence: Reliance on healthcare providers and pharmaceutical companies for revenue.
  • Regulatory Risks: Compliance with stringent healthcare and drug development regulations.
  • Supply Chain Disruptions: Potential disruptions in the supply of reagents, equipment, and other critical materials.
  • Competition: Intense competition from established players and new entrants.
  • Economic Conditions: Economic downturns could reduce demand for diagnostic and drug development services.
  • Technological Disruption: Rapid advancements in technology could render some of Labcorp’s services obsolete.

Recent Developments

Labcorp has been actively pursuing initiatives to strengthen its market position and enhance its service offerings. Recent developments include:

  • Acquisition of Myriad Genetics’ Autoimmune Business: This acquisition expands Labcorp’s capabilities in autoimmune diagnostics.
  • Launch of New Tests: Introduction of advanced genetic tests and biomarkers for cancer and other diseases.
  • COVID-19 Response: Continued investment in COVID-19 testing and vaccine-related services.
  • Digital Transformation: Expansion of its Pixel by Labcorp platform to offer more at-home testing options.
  • Global Partnerships: Collaborations with international healthcare providers to expand its global footprint.

Investment Considerations

Strengths:

  • Market Leadership: Labcorp is a leader in both diagnostics and drug development.
  • Integrated Services: Synergies between its two business segments create a competitive advantage.
  • Global Reach: Presence in over 100 countries provides access to diverse markets.
  • Innovation: Strong focus on research and development.

Risks:

  • Regulatory Challenges: Compliance with complex regulations can be costly and time-consuming.
  • Economic Sensitivity: Demand for services may fluctuate with economic conditions.
  • Competition: Intense competition could pressure margins.

Conclusion

Labcorp is a global leader in diagnostics and drug development, with a strong market position and a comprehensive suite of services. The company’s integrated business model, focus on innovation, and commitment to sustainability position it well for future growth. However, it faces challenges such as regulatory compliance, competition, and economic sensitivity. Overall, Labcorp remains a compelling choice for investors seeking exposure to the healthcare and life sciences sectors.